NASDAQ: EXOZ · Life Sciences · 4 alerts · CIK 2010788
Share price
$3.99Close, Nov 16
Market cap
$37.7M
Shares outstanding
9.44MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Exozymes Inc. filings on SEC EDGAR ↗
EXOZYMES INC. reported a net loss of $7.49 million for the nine months ended September 30, 2026, compared to a $6.50 million loss in the prior year. The company remains in a development stage with no operating income, primarily funded by a public offering and registered direct offering that raised approximately $5.86 million in net proceeds during the period.
Exozymes Chief Commercial Officer Damien Alan Perriman Sells $19.4K of Stock
Damien Alan Perriman, Chief Commercial Officer, sold 3,729 shares of Exozymes Inc. at $5.21 a share, worth $19.4K in total on Oct 12, 2026. Shares held after the trade: 28,692 (-11.5%).
eXoZymes Inc. filed a formal Investor Presentation dated October 6, 2026, to be shared with investment bankers and potential investors. The presentation provides strategic highlights and business updates for the company's current and future stakeholders.
Exozymes Inc. has scheduled its 2026 Annual Meeting of Shareholders for November 13, 2026. The company established a record date of September 15, 2026, and plans to distribute proxy materials to shareholders on or about September 28, 2026.